Literature DB >> 23715768

Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.

F A Di Lello1, A Caruz, N I Rallon, A Rivero-Juarez, K Neukam, P Barreiro, A Camacho, S García-Rey, A Rivero, V Soriano, C Cifuentes, J Macias, J A Pineda.   

Abstract

The aim of this study was to assess the impact of the genetic pattern (GP) defined by the single nucleotide polymorphisms (SNPs) rs14158 of low-density lipoprotein receptor (LDLR) and rs12979860 of interleukin-28B (IL28B) genes on the outcome and features of hepatitis C virus (HCV) infection in patients with and without human immunodeficiency virus (HIV) coinfection. 314 HIV/HCV-coinfected and 109 HCV-monoinfected patients treated with pegylated interferon (Peg-IFN) plus ribavirin (RBV), as well as 51 patients with HCV spontaneous clearance (SC), were included. Variations in both SNPs were determined by the TaqMan polymerase chain reaction (PCR) assay. In the 286 patients chronically infected by HCV genotypes 1 or 4, both rs14158 CC and rs12979860 CC were associated with a higher rate of sustained virological response (SVR), and these effects were complementary in both HCV-monoinfected and HIV/HCV-coinfected patients. Thus, 24 % of patients with rs14158/rs12979860 TT-TC/TT-TC, 33 % with TT-TC/CC, 44.2 % with CC/TT-TC, and 75.8 % harboring CC/CC attained SVR (p < 0.001). SC was associated with the IL28B genotype (66.7 % CC in SC vs. 42.6 % among those with chronic infection, p < 0.001) but not with the LDLR genotype. There was no association between GP and the plasma level of alanine aminotransferase (ALT) or the presence of advanced fibrosis. There is a complementary effect between the IL28B and LDLR genotypes on the probability of achieving SVR after Peg-IFN/RBV therapy in patients with HCV 1 or 4. Thus, the predictive value of IL28B genotype is modulated by the LDLR genotype in both HCV-monoinfected and HIV/HCV-coinfected patients. This complementary effect of both genotypes is also observed on the plasma levels of low-density lipoprotein cholesterol (LDL-C).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715768     DOI: 10.1007/s10096-013-1894-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  28 in total

1.  Quantitative effects of common genetic variations in the 3'UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the Atherosclerosis Risk in Communities study.

Authors:  Hind Muallem; Kari E North; Masao Kakoki; Mary K Wojczynski; Xia Li; Megan Grove; Eric Boerwinkle; Kirk C Wilhelmsen; Gerardo Heiss; Nobuyo Maeda
Journal:  Hum Genet       Date:  2007-02-02       Impact factor: 4.132

2.  Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.

Authors:  José del Valle; José A Mira; Ignacio de los Santos; Luis F López-Cortés; Dolores Merino; Antonio Rivero; José A Girón; María J Ríos-Villegas; Mercedes González-Serrano; Antonio Collado; José A García-García; Juan A Pineda
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

3.  Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

Authors:  Juan A Pineda; Antonio Caruz; Federico A Di Lello; Angela Camacho; Pilar Mesa; Karin Neukam; Antonio Rivero-juárez; Juan Macías; Jesús Gómez-Mateos; Antonio Rivero
Journal:  AIDS       Date:  2011-07-17       Impact factor: 4.177

4.  Beta-lipoproteins influence the serum level of hepatitis C virus.

Authors:  M Enjoji; M Nakamuta; N Kinukawa; R Sugimoto; K Noguchi; S Tsuruta; M Iwao; K Kotoh; H Iwamoto; H Nawata
Journal:  Med Sci Monit       Date:  2000 Sep-Oct

5.  Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Authors:  Stephen A Harrison; Lorenzo Rossaro; Ke-Qin Hu; Keyur Patel; Hans Tillmann; Sandeep Dhaliwal; Dawn M Torres; Kenneth Koury; Venkata S Goteti; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

Authors:  Pablo Barreiro; Juan Antonio Pineda; Norma Rallón; Susanna Naggie; Luz Martín-Carbonero; Karin Neukam; Antonio Rivero; José Miguel Benito; Antonio Caruz; Eugenia Vispo; Angela Camacho; José Medrano; John McHutchison; Vincent Soriano
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

7.  Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Authors:  Juan A Pineda; Antonio Caruz; Antonio Rivero; Karin Neukam; Irene Salas; Angela Camacho; José C Palomares; José A Mira; Antonio Martínez; Carmen Roldán; Julián de la Torre; Juan Macías
Journal:  Clin Infect Dis       Date:  2010-10-01       Impact factor: 9.079

8.  Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection.

Authors:  B J W Hennig; S Hellier; A J Frodsham; L Zhang; P Klenerman; S Knapp; M Wright; H C Thomas; M Thursz; A V S Hill
Journal:  Genes Immun       Date:  2002-09       Impact factor: 2.676

9.  Stabilization and cytoskeletal-association of LDL receptor mRNA are mediated by distinct domains in its 3' untranslated region.

Authors:  G M Wilson; M Z Vasa; R G Deeley
Journal:  J Lipid Res       Date:  1998-05       Impact factor: 5.922

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  2 in total

1.  Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis.

Authors:  Chrissa G Tsiara; Georgios K Nikolopoulos; Niki L Dimou; Katerina G Pantavou; Pantelis G Bagos; Benedicta Mensah; Michael Talias; Georgia G Braliou; Dimitra Paraskeva; Stefanos Bonovas; Angelos Hatzakis
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

2.  Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection.

Authors:  Luis Miguel Real; Juan Macías; Antonio Rivero-Juárez; Francisco Téllez; Dolores Merino; Sonia Moreno-Grau; Adelina Orellana; Juan Gómez-Salgado; María E Sáez; Mario Frías; Anaïs Corma-Gómez; Nicolás Merchante; Agustín Ruiz; Antonio Caruz; Juan A Pineda
Journal:  Sci Rep       Date:  2019-06-21       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.